The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma

Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the profound immunosup...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 15; no. 4; p. 1134
Main Authors Neth, Bryan J, Webb, Mason J, Parney, Ian F, Sener, Ugur T
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.04.2023
MDPI
Subjects
adjuvant
Antigens
Brain cancer
Brain research
Cancer therapies
Cancer vaccines
Care and treatment
Chemotherapy
Clinical trials
dendritic cell
Dosage and administration
FDA approval
Forecasts and trends
GBM
glioblastoma
Glioblastoma multiforme
Growth factors
Heat shock proteins
Immunotherapy
Lymphocytes
Metastasis
Mutation
Nervous system
Peptides
Plasmids
Prognosis
Radiation therapy
Review
Tumors
vaccine
United States
vaccine
GBM
glioblastoma
adjuvant
dendritic cell
Online AccessGet full text

Cover

More Information
Summary:Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the profound immunosuppressive microenvironment seen in GBMs, there has been a broad interest in immunotherapy. In both GBMs and other cancers, therapeutic vaccines have generally yielded limited efficacy, despite their theoretical basis. However, recent results from the DCVax-L trial provide some promise for vaccine therapy in GBMs. There is also the potential that future combination therapies with vaccines and adjuvant immunomodulating agents may greatly enhance antitumor immune responses. Clinicians must remain open to novel therapeutic strategies, such as vaccinations, and carefully await the results of ongoing and future trials. In this review of GBM management, the promise and challenges of immunotherapy with a focus on therapeutic vaccinations are discussed. Additionally, adjuvant therapies, logistical considerations, and future directions are discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15041134